Elicio Therapeutics Reports Inducement Grants

Rhea-AI Summary

Elicio Therapeutics (Nasdaq: ELTX) announced on January 16, 2026 that on January 15, 2026 it granted an aggregate of 22,400 inducement stock options to two new employees under the 2024 Inducement Incentive Award Plan as permitted by Nasdaq Listing Rule 5635(c)(4). The grants were approved by the Compensation Committee and set the exercise price at $7.81 per share, the Nasdaq closing price on the grant date. The options vest over four years with 25% vesting on the first anniversary of each employee’s start date and the remainder vesting ratably each month thereafter, subject to continued service.

Argus Jan 16 session

+5.63% close to close Open Argus

Details

News Market Reaction – ELTX

On Jan 16, the day this news came out, ELTX closed 5.63% above the previous close.

Data tracked by StockTitan Argus for the Jan 16 session.

Market Context

On Jan 16, the day this news came out, the stock closed 5.6% above the previous close. A strong posi...

Analysis

On Jan 16, the day this news came out, the stock closed 5.6% above the previous close. A strong positive reaction aligns with the stock’s sensitivity to news flow, even for routine items. Prior clinical updates and corporate actions have sometimes produced sizable moves despite limited fundamental change. Investors may weigh this announcement against existing capital structures, including the S-3 resale registration for 103,225 warrant shares. If enthusiasm stemmed from technical factors, the effect could fade as trading normalizes around the $7.81 reference price.

Key Figures

Inducement options: 22,400 options Option exercise price: $7.81 per share Vesting schedule: 4 years; 25% at year 1 +5 more

Inducement options

22,400 options

Aggregate inducement stock options granted to two new employees

Option exercise price

$7.81 per share

Inducement grant exercise price equal to Jan 15, 2026 Nasdaq close

Vesting schedule

4 years; 25% at year 1

25% on first anniversary, remainder monthly thereafter

Registered warrant shares

103,225 shares

Shares covered by resale registration on S-3 for GKCC, LLC warrant

Warrant exercise price

$7.75 per share

Exercise price of warrant registered on S-3

Ownership cap

49.99%

Beneficial ownership limitation on warrant exercise

Q3 2025 net loss

$10.1M

Quarter ended September 30, 2025

Cash and equivalents

$20.6M

Balance as of September 30, 2025, supporting operations through Q2 2026

Historical Context

5 past events · Latest: Dec 16

5 events

1. Dec 16

   Inducement grants

   24h Move

   -4.3%

   Reported 157,193 inducement stock options at $8.52 with four-year vesting.

2. Dec 11

   Clinical trial data

   24h Move

   +4.0%

   Phase 2 AMPLIFY-7P antigen spreading results showing strong T cell responses.

3. Nov 19

   Executive appointment

   24h Move

   -5.5%

   Appointment of CTO to lead CMC, development, manufacturing and supply chain.

4. Nov 13

   Earnings and update

   24h Move

   -0.9%

   Q3 2025 results with DFS analysis timing and cash runway through Q2 2026.

5. Nov 07

   Clinical trial data

   24h Move

   -2.2%

   Updated AMPLIFY-7P immunogenicity and ELI-004 preclinical data at SITC.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

inducement stock options, nasdaq listing rule 5635(c)(4)

2 terms

inducement stock options financial

"granted an aggregate of 22,400 inducement stock options to two new employees"

Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.

nasdaq listing rule 5635(c)(4) regulatory

"with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on January 15, 2026, Elicio granted an aggregate of 22,400 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.

Each grant provides for the purchase of shares of Elicio common stock at a price of $7.81 per share, the closing price per share of Elicio common stock as reported by Nasdaq on January 15, 2026, the date of grant.

The grants vest over four years, with 25 percent of the shares vesting on the first anniversary of each employee’s respective start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to such employee’s continued service relationship with Elicio through the applicable vesting dates.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drives approximately 25% of all solid tumors. Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid commercial scale manufacturing, and rapid availability of drug to patients especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. ELI-002 is being studied in an ongoing, randomized clinical trial in patients with mKRAS-positive pancreatic cancer who completed standard therapy but remain at high risk of relapse. ELI-002 also has been studied in patients with mKRAS-positive colorectal cancer (“CRC”) in Phase 1 studies. The updated AMPLIFY-201 Phase 1 data for PDAC and CRC was presented at the ESMO Immuno-Oncology Congress 2024 and included a 16.3-month median recurrence-free survival and 28.9-month median overall survival for the full study population. In the future, Elicio plans to expand ELI-002 to other indications including mKRAS positive lung cancer and other mKRAS positive cancers. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.

Investor Relations Contact
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many inducement stock options did Elicio Therapeutics (ELTX) grant on January 15, 2026?

Elicio granted an aggregate of 22,400 inducement stock options to two new employees on January 15, 2026.

What exercise price was set for the ELTX inducement options granted January 15, 2026?

The exercise price for the grants was $7.81 per share, the Nasdaq closing price on January 15, 2026.

What is the vesting schedule for the ELTX inducement options granted January 15, 2026?

The options vest over four years: 25% on the first anniversary of each employee’s start date and the remainder vesting ratably each subsequent month, subject to continued service.

Under which plan and approval authority were the ELTX inducement options granted?

The options were granted under the Elicio Therapeutics 2024 Inducement Incentive Award Plan and were approved by the company’s Compensation Committee.

Why were inducement stock options used for the ELTX hires on January 15, 2026?

The company granted inducement stock options as material inducements for two new hires in accordance with Nasdaq Listing Rule 5635(c)(4).